Egetis Therapeutics Q1: Emcitate is now launched in Germany - Redeye

Egetis delivered sales along expectations with reasonable cost control, and more importantly, the German launch is underway following the European approval in February, supported by the earlier European Thyroid Association guidelines in August 2024. We look forward to feedback from the launch and the publication of recent trial results in Brazil (June) over the coming months.

Länk till analysen i sin helhet: https://www.redeye.se/research/1101485/egetis-therapeutics-q1-emcitate-is-now-launched-in-germany?utm_source=finwire&utm_medium=RSS